Lynparza Shrinks Breast Cancer Tumors at Double the Rate of Chemo, Study Shows

Lynparza Shrinks Breast Cancer Tumors at Double the Rate of Chemo, Study Shows
The ovarian cancer therapy Lynparza (olaparib) shrank the tumors of 60 percent of breast cancer patients treated with it, double the figure for standard chemotherapy, according to a study. Lynparza, a PARP inhibitor, also increased by two-thirds the time it took for breast cancer to progress after treatment— seven months, versus 4.2 with chemo, researchers said. The results applied to breast cancer caused by BRCA gene mutations. Lynparza, which was developed by AstraZeneca, is used to treat advanced ovarian cancer with the same mutation. BRCA mutations are responsible for 3 percent of breast cancer worldwide. The cases are very difficult to treat, and many women with the mutations decide to remove their breasts before developing signs of the cancer. Angelina Jolie’s case cast a global spotlight on the procedure, known as prophylactic mastectomy. AstraZeneca discussed Phase 3 clinical trial results of Lynparza's ability to treat breast cancer at the annual meeting of the American Society of Clinical Oncology in Chicago. The convention, which started June 2, finished June 6. The presentation was titled “OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).” The Phase 3 OlympiAD study (
Subscribe or to access all post and page content.